Introduction

Female mammals have a unique mechanism of gene dosage compensation called X-chromosome inactivation (XCI), which is an essential epigenetic process for development. In mice, inactivation of the paternally derived X chromosome (Xp), but not of the maternally derived X chromosome (Xm), is initiated in the preimplantation embryos (imprinted XCI)1,2,3. This imprinted inactivation of the Xp is maintained in post-implantation extra-embryonic tissues. At the blastocyst stage, reactivation of the Xp occurs in the inner cell mass that will later form the embryo. Thus, the imprinted XCI is erased once, subsequently, random XCI of either the Xp or Xm chromosomes is initiated in the post-implantation embryo by a cis-acting region on the X chromosome termed the X-inactivation centre (** are shown as red arrows. (b) Validation of recombination on the chromosomal long and short arm target sequences of ES cells (cell lines #64 and #77). (c) Genoty** results for wild-type females (+m/+p, where m is the maternally derived X chromosome and p is the paternally derived X chromosome), heterozygous females (+m/−p), homozygous females (−m/−p), wild-type males (+m/Y, where Y is the Y chromosome) and hemizygous males (−m/Y). The PCR primers (233, 234, and330) used for genoty** are depicted in Fig2-a. (d) Expression of Ftx in Ftx-deficient blastocysts. PCR primers used for RT–PCR are shown in parentheses. Uncropped images of the full-length gels are presented in Supplementary Figure S1. (e) The expression levels of miR-374-5p and miR-421-3p were quantified by q-PCR in wild-type female (+m/+p), male (+m/Y) and heterozygous female (+m/−p) blastocysts. The ratios of the number of cDNA copies for each miRNA to that of cDNA copies for miR-295 are indicated as expression levels. The bar graphs and lines show the mean ± standard deviation (SD) (n = 3).